Veradermics, Inc.
Veradermics is a biopharmaceutical company focused on advancing first-in-class therapeutics that address common dermatologic and aesthetic conditions. The company aims to disrupt the dermatology landscape by developing innovative solutions for underserved markets, improving treatment outcomes, and establishing new industry standards. Led by a team of dermatologists and industry experts, Veradermics leverages clinical experience to identify and develop novel drugs targeting conditions such as alopecia, warts, molluscum contagiosum, and atopic dermatitis.
Industries
Nr. of Employees
small (1-50)
Veradermics, Inc.
470 James St., Suite 14, New Haven, CT 06513
Patents
Products
Non-hormonal oral therapy for pattern hair loss (VDPHL01)
Investigational, non-hormonal oral small-molecule therapeutic in clinical development for androgenetic alopecia/pattern hair loss.
Dissolvable microarray immunotherapy patch for common warts (VDMN)
Investigational dissolvable microarray patch delivering an antigen extract to stimulate local immune clearance of common warts without injection.
Topical immunotherapy for alopecia areata (VDAA)
Topical, contact immunotherapy candidate intended for monthly application to treat all severities of alopecia areata.
Topical antiviral candidate for molluscum contagiosum (VDMC-7269)
Preclinical/new chemical entity topical antiviral designed to inhibit poxvirus replication with limited systemic absorption, advanced via an academic license.
Oral immunomodulator for atopic dermatitis (VDAD)
Preclinical oral new chemical entity intended to modulate immune response for treatment of atopic dermatitis.
Non-hormonal oral therapy for pattern hair loss (VDPHL01)
Investigational, non-hormonal oral small-molecule therapeutic in clinical development for androgenetic alopecia/pattern hair loss.
Dissolvable microarray immunotherapy patch for common warts (VDMN)
Investigational dissolvable microarray patch delivering an antigen extract to stimulate local immune clearance of common warts without injection.
Topical immunotherapy for alopecia areata (VDAA)
Topical, contact immunotherapy candidate intended for monthly application to treat all severities of alopecia areata.
Topical antiviral candidate for molluscum contagiosum (VDMC-7269)
Preclinical/new chemical entity topical antiviral designed to inhibit poxvirus replication with limited systemic absorption, advanced via an academic license.
Oral immunomodulator for atopic dermatitis (VDAD)
Preclinical oral new chemical entity intended to modulate immune response for treatment of atopic dermatitis.
Services
Engagements to discuss licensing, product development partnerships, and strategic alliances for dermatology therapeutics.
Engagements to discuss licensing, product development partnerships, and strategic alliances for dermatology therapeutics.
Expertise Areas
- Clinical trial management (Phase 1–3, multicenter)
- Dermatology drug development
- Transdermal delivery and microarray platform development
- Antiviral discovery and topical drug development
Key Technologies
- Dissolvable microarray transdermal patch
- Topical antiviral small molecules
- Oral small-molecule therapeutics
- Antigen-based immunotherapy formulations
News & Updates
Veradermics announced the closing of a $75 million Series B financing to fund pivotal trials of VDPHL01, an oral investigational medicine for androgenetic alopecia (AGA). The company has also initiated a Phase 2/3 trial for this product.
Reid Waldman, CEO of Veradermics, was recognized in Forbes 30 Under 30 list for 2024, acknowledging his leadership and the company's progress in developing dermatological therapeutics.
The company has commenced dosing in a clinical trial for VDPHL, a non-hormonal oral treatment for pattern hair loss, targeting a large unmet market.
VeraDermics entered into a license agreement with the University of Pennsylvania for a compound targeting molluscum contagiosum, aiming to develop a first-in-class topical antiviral.
An article discussing new therapeutic options for androgenetic alopecia, highlighting Veradermics' pipeline.
Coverage on a new hair loss treatment developed by Veradermics, with details on clinical trials and development.
Veradermics announced the closing of a $75 million Series B financing to fund pivotal trials of VDPHL01, an oral investigational medicine for androgenetic alopecia (AGA). The company has also initiated a Phase 2/3 trial for this product.
Reid Waldman, CEO of Veradermics, was recognized in Forbes 30 Under 30 list for 2024, acknowledging his leadership and the company's progress in developing dermatological therapeutics.
The company has commenced dosing in a clinical trial for VDPHL, a non-hormonal oral treatment for pattern hair loss, targeting a large unmet market.
VeraDermics entered into a license agreement with the University of Pennsylvania for a compound targeting molluscum contagiosum, aiming to develop a first-in-class topical antiviral.
An article discussing new therapeutic options for androgenetic alopecia, highlighting Veradermics' pipeline.
Coverage on a new hair loss treatment developed by Veradermics, with details on clinical trials and development.